Corporate and Regional Press Releases

Please find below a list of our press releases.

29 Apr 2019

Trial finds patients receiving CroFab® antivenom less likely to use opioids for pain control

BTG plc, the global healthcare company, today announced the publication of a trial, "Antivenom Treatment is Associated with Fewer Patients Using Opioids after Copperhead Envenomation" in the Western Journal of Emergency Medicine (WestJEM).

29 Apr 2019

Venous Leg Ulcer Registry Shows Promising Results for Varithena® Use in Wound Healing 

BTG plc today highlighted the VIEW VLU Registry interim study results, presented at the International Vein Congress in Miami, Florida. The interim findings confirm that Varithena® polidocanol injectable foam 1% shows promise in increasing the rate of wound healing.

18 Apr 2019

BTG plc: close period update

BTG plc (LSE: BTG), the global healthcare company, provides the following update for the 12 months ended 31 March 2019.

7 Mar 2019

BTG Crossing Devices are Highlighted at the CTO Summit in NY

BTG, the global healthcare company, exhibited the BTG Crossing Devices portfolio at the Chronic Total Occlusion (CTO) Summit in New York City from February 28 to March 1. Dr. Alexandre Avran of the Arnault Tzanck Institute in Nice, France, headlined the BTG exhibition at the summit this year, discussing his experience with the devices at a lunch symposium.

5 Mar 2019

New research validates clinical value of treating Copperhead envenomation with CroFab®

BTG announced that research published today in PLOS ONE establishes the Patient-Specific Functional Scale (PSFS) as a valid, reliable, and clinically meaningful measure for assessing quality of life and functionality in snake envenomation studies.

14 Feb 2019

A Retrospective Study of Medicare claim data shows patients treated with Voraxaze® had shorter hospitalizations and lower mortality

BTG plc (LSE: BTG), the global healthcare company, today announced the publication of data showing that cancer patients with presumed methotrexate toxicity treated with Voraxaze® (glucarpidase) had shorter hospital stays, lower in-patient mortality, and lower 90-day mortality than those treated with conventional treatment. The study, based on a retrospective review of Medicare claim data, was published in the journal ClinicoEconomics and Outcomes Research.

5 Feb 2019

NHS England expands loco-regional treatment options for colorectal cancer patients with metastatic disease.

BTG plc (LSE: BTG), a global healthcare company, today announced that the NHS Specialised Services Commissioning Committee has agreed that, effective 1 April 2019, NHS England will routinely commission Selective Internal Radiation Therapy (SIRT) for colorectal cancer patients with liver-limited metastatic disease who are refractory or intolerant to chemotherapy.

21 Jan 2019

Australian Patient Treated With DC Bead LUMI™, the first commercially available Radiopaque Drug-Eluting Bead

BTG plc (LSE: BTG), a global specialist healthcare company, today announced the treatment of an Australian patient with DC Bead LUMI™, a next-generation development of the market leading DC Bead®.

8 Jan 2019

BTG and OMNY Partner to Improve Treatment of Snake Bite Victims

Distributed ledger technology is a game changer for managing stock levels of critical antidote.

21 Dec 2018

BTG announces National Reimbursement for TheraSphere® in France 

An estimated 500 patients per year in France could be eligible for treatment with TheraSphere®